Upgrading and Downgrading of Prostate Needle Biopsy Specimens: Risk Factors and Clinical Implications - 15/08/11
†, ⁎ 
, Christopher J. Kane ‡, §, Christopher L. Amling ¶, 
, William J. Aronson #, , Martha K. Terris ††, ‡‡, Joseph C. Presti §§, ¶¶SEARCH Database Study Group
Department of Surgery, Durham Veterans Affairs Medical Center, Durham, North Carolina Department of Urology, San Diego Naval Hospital, San Diego, California Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California Reprint requests: Stephen J. Freedland, M.D., Division of Urology, Box 3850 DUMC, Duke University School of Medicine, Durham, NC 27710.Résumé |
Objectives |
The prostate biopsy Gleason grade frequently differs from the radical prostatectomy (RP) grade. Given the critical role that needle biopsy plays in treatment decisions, we sought to determine the risk factors for upgrading and downgrading the prostate biopsy specimen.
Methods |
We determined the significant predictors of upgrading (worse RP grade than biopsy grade) and downgrading (better RP grade than biopsy grade) among 1113 men treated with RP from 1996 to 2005 within the Shared Equal Access Regional Cancer Hospital (SEARCH) database who had undergone at least sextant biopsy. The Gleason sum was examined as a categorical variable of 2 to 6, 3+4, and 4+3 or greater.
Results |
Overall, the disease of 299 men (27%) was upgraded and 123 (11%) was downgraded, and 691 men (62%) had identical biopsy and pathologic Gleason sum groups. Upgrading was associated with adverse pathologic features (P ≤0.001) and the risk of biochemical progression (P = 0.001). Downgrading was associated with more favorable pathologic features (P ≤0.01) and a decreased risk of progression (P = 0.04). On multivariate analysis, greater prostate-specific antigen levels (P <0.001), more biopsy cores with cancer (P = 0.001), and obesity (P = 0.003) were all significantly and positively associated with upgrading. In contrast, biopsy Gleason sum 3+4 (P = 0.001) and obtaining eight or more biopsy cores (P = 0.01) were associated with a lower likelihood of upgrading.
Conclusions |
Men whose disease was upgraded were at a greater risk of adverse pathologic features and biochemical progression. Men with “high-risk” cancer (greater prostate-specific antigen levels, more positive cores, and obese) were more likely to have their disease category upgraded, and obtaining more biopsy cores reduced the likelihood of upgrading.
Le texte complet de cet article est disponible en PDF.Plan
| This study was supported by the Department of Veterans Affairs, National Institutes of Health grant R01CA100938 (W.J. Aronson), National Institutes of Health Specialized Programs of Research Excellence grant P50 CA92131-01A1 (W. J. Aronson), the Georgia Cancer Coalition (M. K. Terris), Department of Defense, Prostate Cancer Research Program (S. J. Freedland), and the American Urological Association Foundation/Astellas Rising Star in Urology Award (S. J. Freedland). |
|
| The views and opinions of, and endorsements by the authors do not reflect those of the U.S. Army or the U.S. Department of Defense. |
Vol 69 - N° 3
P. 495-499 - mars 2007 Retour au numéro
Article précédent
- Tramadol Improves Patients’ Tolerance of Transrectal Ultrasound-Guided Prostate Biopsy
- Irina Hirsh, Alexander Kaploun, Gazy Faris, Boaz Appel, Ilia Shneider, Avi Stein, Reuven Pizov
- Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer
- Juan Morote, Jacques Planas Morin, Anna Orsola, Jose M. Abascal, Carles Salvador, Enrique Trilla, Carles X. Raventos, Lluis Cecchini, Gloria Encabo, Jaume Reventos
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?